161 related articles for article (PubMed ID: 16536473)
1. Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT).
Alderson RF; Toki BE; Roberge M; Geng W; Basler J; Chin R; Liu A; Ueda R; Hodges D; Escandon E; Chen T; Kanavarioti T; Babé L; Senter PD; Fox JA; Schellenberger V
Bioconjug Chem; 2006; 17(2):410-8. PubMed ID: 16536473
[TBL] [Abstract][Full Text] [Related]
2. Construction and optimization of a CC49-based scFv-beta-lactamase fusion protein for ADEPT.
Roberge M; Estabrook M; Basler J; Chin R; Gualfetti P; Liu A; Wong SB; Rashid MH; Graycar T; Babé L; Schellenberger V
Protein Eng Des Sel; 2006 Apr; 19(4):141-5. PubMed ID: 16436454
[TBL] [Abstract][Full Text] [Related]
3. Development and activities of a new melphalan prodrug designed for tumor-selective activation.
Kerr DE; Li Z; Siemers NO; Senter PD; Vrudhula VM
Bioconjug Chem; 1998; 9(2):255-9. PubMed ID: 9548542
[TBL] [Abstract][Full Text] [Related]
4. Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy.
Sharma SK; Pedley RB; Bhatia J; Boxer GM; El-Emir E; Qureshi U; Tolner B; Lowe H; Michael NP; Minton N; Begent RH; Chester KA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):814-25. PubMed ID: 15701872
[TBL] [Abstract][Full Text] [Related]
5. Improved yield and stability of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineering.
McDonagh CF; Beam KS; Wu GJ; Chen JH; Chace DF; Senter PD; Francisco JA
Bioconjug Chem; 2003; 14(5):860-9. PubMed ID: 13129388
[TBL] [Abstract][Full Text] [Related]
6. Genetic construction, expression, and characterization of a single chain anti-carcinoma antibody fused to beta-lactamase.
Goshorn SC; Svensson HP; Kerr DE; Somerville JE; Senter PD; Fell HP
Cancer Res; 1993 May; 53(9):2123-7. PubMed ID: 8481914
[TBL] [Abstract][Full Text] [Related]
7. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment.
Chen KC; Wu SY; Leu YL; Prijovich ZM; Chen BM; Wang HE; Cheng TL; Roffler SR
Bioconjug Chem; 2011 May; 22(5):938-48. PubMed ID: 21443266
[TBL] [Abstract][Full Text] [Related]
8. Comparison of recombinant and synthetically formed monoclonal antibody-beta-lactamase conjugates for anticancer prodrug activation.
Kerr DE; Vrudhula VM; Svensson HP; Siemers NO; Senter PD
Bioconjug Chem; 1999; 10(6):1084-9. PubMed ID: 10563779
[TBL] [Abstract][Full Text] [Related]
9. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
Biela BH; Khawli LA; Hu P; Epstein AL
Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
[TBL] [Abstract][Full Text] [Related]
10. Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation.
Siemers NO; Kerr DE; Yarnold S; Stebbins MR; Vrudhula VM; Hellström I; Hellström KE; Senter PD
Bioconjug Chem; 1997; 8(4):510-9. PubMed ID: 9258449
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein.
Hao XK; Liu JY; Yue QH; Wu GJ; Bai YJ; Yin Y
Prostate; 2006 Jun; 66(8):858-66. PubMed ID: 16491483
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody-beta-lactamase conjugates for the activation of a cephalosporin mustard prodrug.
Svensson HP; Kadow JF; Vrudhula VM; Wallace PM; Senter PD
Bioconjug Chem; 1992; 3(2):176-81. PubMed ID: 1515470
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH
Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598
[TBL] [Abstract][Full Text] [Related]
14. Site-specific prodrug activation by antibody-beta-lactamase conjugates: preclinical investigation of the efficacy and toxicity of doxorubicin delivered by antibody directed catalysis.
Meyer DL; Law KL; Payne JK; Mikolajczyk SD; Zarrinmayeh H; Jungheim LN; Kling JK; Shepherd TA; Starling JJ
Bioconjug Chem; 1995; 6(4):440-6. PubMed ID: 7578364
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG
Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451
[TBL] [Abstract][Full Text] [Related]
16. Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104.
Liu SC; Ahn GO; Kioi M; Dorie MJ; Patterson AV; Brown JM
Cancer Res; 2008 Oct; 68(19):7995-8003. PubMed ID: 18829557
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effects of monoclonal antibody-beta-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma.
Svensson HP; Frank IS; Berry KK; Senter PD
J Med Chem; 1998 Apr; 41(9):1507-12. PubMed ID: 9554883
[TBL] [Abstract][Full Text] [Related]
18. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts.
Blakey DC; Burke PJ; Davies DH; Dowell RI; East SJ; Eckersley KP; Fitton JE; McDaid J; Melton RG; Niculescu-Duvaz IA; Pinder PE; Sharma SK; Wright AF; Springer CJ
Cancer Res; 1996 Jul; 56(14):3287-92. PubMed ID: 8764123
[TBL] [Abstract][Full Text] [Related]
19. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker.
Conover CD; Greenwald RB; Pendri A; Gilbert CW; Shum KL
Cancer Chemother Pharmacol; 1998; 42(5):407-14. PubMed ID: 9771956
[TBL] [Abstract][Full Text] [Related]
20. Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy.
Heinis C; Alessi P; Neri D
Biochemistry; 2004 May; 43(20):6293-303. PubMed ID: 15147213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
